Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-1.5
% (year-on-year change in consolidated net sales)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentation materialsSecond quarter of the fiscal year ending March 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,393 million-1.5%
Operating profit¥29 million-77.0%
Ordinary income¥38 million-71.8%
Net income¥42 million-49.5%
Gross Profit Margin58.2 %
Operating profit margin2.1 %
Selling, general and administrative expenses¥781 million
Full-year earnings forecast
Net Sales
¥3,100 million
Operating profit
¥100 million
Domestic revenue
¥3,000 million
Overseas Sales
¥100 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales
Progress against full-year forecast45 %
Second-quarter basis50 %
Operating profit
Progress against full-year forecast29.9 %
Second-quarter basis50 %
What the company explained in this material
New initiatives
- Expansion of in-person engagement opportunities, including antenatal classes and maternity events
- Joint online seminars with apps for pregnant women
- Bringing advertising operations in-house and strengthening information dissemination through the official website
- Research and development collaboration with CellSource Co.,Ltd.
- Expansion across Southeast Asia centered on a cell processing and storage center in Singapore
Key KPIsA metric the company considers important as a management benchmark.
- Total number of stored specimens6,071 casesYear on year against the same period last year-2.6%
- Umbilical cord blood specimens stored3,506 casesYear on year against the same period last year-5.2%
- Umbilical cord specimens stored2,565 casesYear on year against the same period last year+1.1%
- HOPECELL information requestsShown in monthly graph
- HOPECELL new-plan conversion rateShown in monthly graph
- Cumulative number of Family Supernatant contracts43 cases
Segment results
Domestic
Net Sales
¥1,393 million-1.5%
Operating profit
¥148 million+2.8%
Overseas
Operating profit
¥-118 million
Medium-term management plan targets
Target fiscal yearFiscal year ending March 2030
Net Sales
¥5,500 million
Operating profit
¥1,000 million
Operating profit margin
18.2 %
Market Size / Share
Southeast Asian cord blood banking market
2024
3.16 USD 100 million
2032
10.9 USD 100 million
CAGR16.8 %
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | ¥1,393 million (YoY -1.5%) |
| Operating profit | ¥29 million (YoY -77.0%) |
| Ordinary income | ¥38 million (YoY -71.8%) |
| Net income | ¥42 million (YoY -49.5%) |
| Gross Profit Margin | 58.2 % |
| Operating profit margin | 2.1 % |
| Selling, general and administrative expenses | ¥781 million |
| Full-year earnings forecast | Net Sales ¥3,100 million / Operating profit ¥100 million / Domestic revenue ¥3,000 million / Overseas Sales ¥100 million |
| Progress against full-year forecast | Net Sales Progress against full-year forecast 45 % / Second-quarter basis 50 % / Operating profit Progress against full-year forecast 29.9 % / Second-quarter basis 50 % |
| Segment results | Domestic Net Sales ¥1,393 million (YoY -1.5%) / Operating profit ¥148 million (YoY +2.8%) / Overseas Net Sales Not disclosed / Operating profit ¥-118 million |
| Key KPIs | Indicator name Total number of stored specimens / Value 6,071 cases / Year on year against the same period last year -2.6 cases, Indicator name Umbilical cord blood specimens stored / Value 3,506 cases / Year on year against the same period last year -5.2 cases, Indicator name Umbilical cord specimens stored / Value 2,565 cases / Year on year against the same period last year 1.1 cases, Indicator name HOPECELL information requests / Value Shown in monthly graph / Year on year against the same period last year Not disclosed, Indicator name HOPECELL new-plan conversion rate / Value Shown in monthly graph / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of Family Supernatant contracts / Value 43 cases / Year on year against the same period last year Not disclosed |
| Medium-term management plan targets | Target fiscal year Fiscal year ending March 2030 / Net Sales ¥5,500 million / Operating profit ¥1,000 million / Operating profit margin 18.2 % |
| Market Size / Share | Southeast Asian cord blood banking market 2024 3.16 USD 100 million / 2032 10.9 USD 100 million / CAGR 16.8 % |
| New initiatives | Expansion of in-person engagement opportunities, including antenatal classes and maternity events, Joint online seminars with apps for pregnant women, Bringing advertising operations in-house and strengthening information dissemination through the official website, Research and development collaboration with CellSource Co.,Ltd., Expansion across Southeast Asia centered on a cell processing and storage center in Singapore |
Items this document does not state (15)
Results for the three months of the current quarterSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, the number of requests for information and the conversion rate declined after the campaign offering free storage fees through June ended. In addition, upfront costs associated with launching the Singapore business weighed on consolidated operating profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.